Oragenics (OGEN) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 15, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-32188
Entity Registrant Name	ORAGENICS, INC.
Entity Central Index Key	0001174940
Entity Tax Identification Number	59-3410522
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	4902 Eisenhower Blvd.
Entity Address, Address Line Two	Suite 125
Entity Address, City or Town	Tampa
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33634
City Area Code	813
Local Phone Number	286-7900
Title of 12(b) Security	Common Stock
Trading Symbol	OGEN
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		116,194,806

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 34,574,769	$ 17,639,575
Prepaid expenses and other current assets	86,917	343,106
Total current assets	34,661,686	17,982,681
Property and equipment, net	18,085	42,713
Operating lease right-of-use assets	567,766	655,138
Total assets	35,247,537	18,680,532
Current liabilities:
Accounts payable and accrued expenses	1,930,271	937,020
Short-term notes payable		228,227
Operating lease liabilities	185,689	176,900
Total current liabilities	2,115,960	1,342,147
Long-term liabilities:
Operating lease liabilities	398,177	493,790
Total long-term liabilities	398,177	493,790
Shareholders’ equity:
Preferred stock, no par value; 50,000,000 shares authorized; 9,417,000 and 9,417,000 Series A shares, 6,600,000 and 6,600,000 Series B shares, -0- and 133.483 Series C shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	2,656,713	7,174,854
Common stock, $0.001 par value; 200,000,000 shares authorized; 116,194,806 and 91,766,928 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	116,195	91,767
Additional paid-in capital	194,558,298	164,022,957
Accumulated deficit	(164,597,806)	(154,444,983)
Total shareholders’ equity	32,733,400	16,844,595
Total liabilities and shareholders’ equity	$ 35,247,537	$ 18,680,532

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0	$ 0
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	116,194,806	91,766,928
Common stock, shares outstanding	116,194,806	91,766,928
Series A Preferred Stock [Member]
Preferred stock, shares issued	9,417,000	9,417,000
Preferred stock, shares outstanding	9,417,000	9,417,000
Series B Preferred Stock [Member]
Preferred stock, shares issued	6,600,000	6,600,000
Preferred stock, shares outstanding	6,600,000	6,600,000
Series C Preferred Stock [Member]
Preferred stock, shares issued	0	133.483
Preferred stock, shares outstanding	0	133.483

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating expenses:
Research and development	$ 2,467,575	$ 11,543,973	$ 5,728,479	$ 15,256,652
General and administrative	1,370,393	808,333	3,346,969	2,327,416
Total operating expenses	3,837,968	12,352,306	9,075,448	17,584,068
Loss from operations	(3,837,968)	(12,352,306)	(9,075,448)	(17,584,068)
Other income (expense):
Interest income	24,254	16,495	44,287	61,010
Interest expense	(1,033)	(885)	(3,601)	(2,593)
Local business tax	(600)	(600)	(1,200)	(1,200)
Miscellaneous income			670	1,795
Total other income, net	22,621	15,010	40,156	59,012
Loss before income taxes	(3,815,347)	(12,337,296)	(9,035,292)	(17,525,056)
Income tax benefit
Net loss	$ (3,815,347)	$ (12,337,296)	$ (9,035,292)	$ (17,525,056)
Basic and diluted net loss per share	$ (0.03)	$ (0.24)	$ (0.08)	$ (0.36)
Shares used to compute basic and diluted net loss per share	115,864,162	52,222,473	109,357,191	49,173,638

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2019	$ 46,125	$ 6,513,396	$ 138,024,957	$ (127,352,826)	$ 17,231,652
Balance, shares at Dec. 31, 2019	46,124,803	16,017,113.941
Compensation expense relating to option issuances			865,110		865,110
Series C dividend		$ 661,458		(661,458)
Series C dividend, shares		19.542
Net loss				(5,187,760)	(5,187,760)
Balance at Mar. 31, 2020	$ 46,125	$ 7,174,854	138,890,067	(133,202,044)	12,909,002
Ending balance, shares at Mar. 31, 2020	46,124,803	16,017,133.483
Balance at Dec. 31, 2019	$ 46,125	$ 6,513,396	138,024,957	(127,352,826)	17,231,652
Balance, shares at Dec. 31, 2019	46,124,803	16,017,113.941
Series C redemption
Net loss					(17,525,056)
Balance at Jun. 30, 2020	$ 55,363	$ 7,174,854	147,097,173	(145,539,340)	8,788,050
Ending balance, shares at Jun. 30, 2020	55,362,803	16,017,133.483
Balance at Mar. 31, 2020	$ 46,125	$ 7,174,854	138,890,067	(133,202,044)	12,909,002
Balance, shares at Mar. 31, 2020	46,124,803	16,017,133.483
Compensation expense relating to option issuances			157,145		157,145
Issuance of common stock from warrant exercise	$ 38		28,462		28,500
Issuance of common stock from warrant exercise, shares	38,000
Issuance of common stock and warrants for the acquisition of Noachis =	$ 9,200		8,021,499		8,030,699
Issuance of common stock and warrants for the acquisition of Noachis, shares	9,200,000
Net loss				(12,337,296)	(12,337,296)
Balance at Jun. 30, 2020	$ 55,363	$ 7,174,854	147,097,173	(145,539,340)	8,788,050
Ending balance, shares at Jun. 30, 2020	55,362,803	16,017,133.483
Balance at Dec. 31, 2020	$ 91,767	$ 7,174,854	164,022,957	(154,444,983)	16,844,595
Balance, shares at Dec. 31, 2020	91,766,928	16,017,133.483
Compensation expense relating to option issuances			1,123,761		1,123,761
Series C dividend		$ 1,117,531		(1,117,531)
Series C dividend, shares		33.016
Series C redemption		$ (5,635,672)			(5,635,672)
Series C redemption, shares		(166.499)
ATM offering - net of expenses	$ 21,399		26,654,993		26,676,392
ATM offering - net of expenses, shares	21,398,765
Issuance of common stock from warrant exercise	$ 2,472		2,258,864		2,261,336
Issuance of common stock from warrant exercise, shares	2,472,573
Net loss				(5,219,945)	(5,219,945)
Balance at Mar. 31, 2021	$ 115,638	$ 2,656,713	194,060,575	(160,782,459)	36,050,467
Ending balance, shares at Mar. 31, 2021	115,638,266	16,017,000
Balance at Dec. 31, 2020	$ 91,767	$ 7,174,854	164,022,957	(154,444,983)	16,844,595
Balance, shares at Dec. 31, 2020	91,766,928	16,017,133.483
Series C redemption					5,635,672
Net loss					(9,035,292)
Balance at Jun. 30, 2021	$ 116,195	$ 2,656,713	194,558,298	(164,597,806)	32,733,400
Ending balance, shares at Jun. 30, 2021	116,194,806	16,017,000
Balance at Mar. 31, 2021	$ 115,638	$ 2,656,713	194,060,575	(160,782,459)	36,050,467
Balance, shares at Mar. 31, 2021	115,638,266	16,017,000
Compensation expense relating to option issuances			231,140		231,140
Issuance of common stock from warrant exercise	$ 557		266,583		267,140
Issuance of common stock from warrant exercise, shares	556,540
Net loss				(3,815,347)	(3,815,347)
Balance at Jun. 30, 2021	$ 116,195	$ 2,656,713	$ 194,558,298	$ (164,597,806)	$ 32,733,400
Ending balance, shares at Jun. 30, 2021	116,194,806	16,017,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (9,035,292)	$ (17,525,056)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	25,176	25,985
Stock-based compensation expense	1,354,901	1,022,255
Stock issued for purchase of Noachis Terra		8,030,699
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	256,189	274,581
Accounts payable and accrued expenses	993,251	(484,159)
Net cash used in operating activities	(6,405,775)	(8,655,695)
Cash flows from financing activities:
Borrowings under short-term notes payable		132,088
Payments on short-term notes payable	(228,227)	(143,864)
Redemption of Series C Preferred stock	(5,635,672)
Proceeds from issuance of common stock for stock option exercise	267,140
Proceeds from issuance of common stock for warrant exercise	2,261,336	28,500
Net proceeds from issuance of common stock	26,676,392
Net cash provided by financing activities	23,340,969	16,724
Net increase (decrease) in cash and cash equivalents	16,935,194	(8,638,971)
Cash and cash equivalents at beginning of period	17,639,575	18,267,994
Cash and cash equivalents at end of period	34,574,769	9,629,023
Supplemental disclosure of cash flow information:
Interest paid	3,601	2,387
Non-cash investing and financing activities:
Stock dividend on Series C preferred stock	$ 1,117,531	$ 661,458

Organization

Organization	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Oragenics, Inc. (formerly known as Oragen, Inc.) (the “Company” or “we”) was incorporated in November, 1996; however, operating activity did not commence until 1999. We are focused on the creation of the Terra CoV-2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease.

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	2. Basis of Presentation The accompanying unaudited interim consolidated financial statements as of June 30, 2021 and December 31, 2020 (audited) and three and six months ended June 30, 2021 and 2020, have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim consolidated financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete consolidated financial statements. In the opinion of management, the accompanying consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the financial condition, results of operations and cash flows for the periods presented. The results of operations for the interim period ended June 30, 2021, are not necessarily indicative of the results of operations that may be expected for the year ended December 31, 2021, or any future period. These consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2020, which are included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021. The Company has incurred recurring losses and negative cash flows from operations since inception. To date, the Company has not generated significant revenues from operations. The Company incurred a net loss of $ 9,035,292 6,405,775 164,597,806 The Company expects to incur substantial expenditures to further develop its technologies. The Company believes the working capital at June 30, 2021 will be sufficient to meet the business objectives as presently structured into the third quarter of 2022. The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new product development. There can be no assurance that any such financing can be realized by the Company, or if realized, what the terms thereof may be, or that any amount that the Company is able to raise will be adequate to support the Company’s working capital requirements until it achieves profitable operations. The Company intends to seek additional funding through sublicensing arrangements, joint venturing or partnering, sales of rights to technology, government grants and public or private financings. The Company’s future success depends on its ability to raise capital and ultimately generate revenue and attain profitability. The Company cannot be certain that additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to it or, if available, will be on terms acceptable to the Company. If the Company issues additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of its common stock, and the Company’s current shareholders may experience dilution. If the Company is unable to obtain funds when needed or on acceptable terms, the Company may be required to curtail its current development programs, cut operating costs and forego future development and other opportunities.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Basis of Consolidation The consolidated financial statements include the accounts of Oragenics, Inc. and our wholly-owned subsidiary Noachis Terra, Inc. All intercompany balances and transactions have been eliminated. New Accounting Standards There are no additional accounting pronouncements issued or effective during the three and six months ended June 30, 2021, that have had, or are expected to have, a material impact on our consolidated financial statements. Recently Issued Accounting Pronouncements Income Taxes In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company’s adoption of the provisions of ASU No. 2019-12, did not have an impact on its consolidated financial statements and related disclosures. Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the consolidated financial statements are stock-based compensation, and valuation of warrants. Stock-Based Payment Arrangements Generally, all forms of stock-based payments, including stock option grants, and warrants are measured at their fair value on the awards’ grant date using a Black-Scholes pricing model. Stock-based compensation awards issued to non-employees for services rendered are recorded at the fair value of the stock-based payment. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided. Stock-based payment expense is recorded over the requisite service period in which the grantee provides services to us. To the extent the stock option grants, warrants, or restricted stock grants do not vest at the grant date they are subject to forfeiture. Stock-Based Compensation US GAAP requires all stock-based payments to employees, including grants of employee stock options, to be recognized in the consolidated financial statements based on their fair values as of the grant date. Stock-based compensation expense is recorded over the requisite service period in which the grantee provides services to us, to the extent the options do not vest at the grant date and are subject to forfeiture. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met. In connection with adopting ASU 2016-09, the Company made an accounting policy election to account for forfeitures in compensation expense as they occur. Warrants The Company used the Black Scholes Option Pricing Model in calculating the relative fair value of any warrants that have been issued. Net Loss Per Share During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive because the Company reported a net loss for all periods presented. Basic and diluted net loss per share amounts are the same for the periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding. Concentrations Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of June 30, 2021, the uninsured portion of this balance was $ 34,324,769 17,389,575

Acquisition

Acquisition	6 Months Ended
	Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Acquisition	4. Acquisition On May 1, 2020, the Company entered into a Stock Purchase Agreement with the sole shareholder of Noachis Terra Inc. (“NTI”), pursuant to which the Company acquired one hundred percent ( 100 %) of the total issued and outstanding common stock of NTI (the “Transaction”). In exchange, the shareholder received the following: (i) cash consideration equal to $ 1,925,000 , of which approximately $ 500,000 was applied to extinguish NTI’s pre-Transaction liabilities (a portion of which were due to the shareholder); (ii) 9,200,000 restricted shares of the Company’s common stock; and (iii) warrants to purchase 9,200,000 shares of the Company’s common stock, which warrants carry an exercise price of $ 1.25 per share, a five-year term, and are exercisable commencing May 1, 2021, the first anniversary of the Transaction’s closing. (i) twenty percent ( 20 0.75 0.90 45 1.00 At the closing of the Transaction, the aggregate fair value of purchase consideration was $ 9,955,699 Schedule of Common Stock, and Contingent Cash Consideration Fair Value Cash - Initial Cash Payment $ 1,925,000 Equity - Common Stock 4,627,600 Equity - Warrants 3,403,099 Total fair value of consideration $ 9,955,699 The Company determined that the acquisition should be accounted for as an asset purchase. The asset which was acquired was in-process research and development which does not have any alternative uses and therefore the aggregate fair value of the purchase price being recorded in research and development expenses in 2020.

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	5. Stock-based Compensation The Company recognized stock-based compensation on all employee and non-employee awards as follows: Schedule of Stock-based Compensation Expense Recognized For the Three Months Ended June 30, 2021 For the Three Months Ended June 30, 2020 For the Six Months Ended June 30, 2021 For the Six Months Ended June 30, 2020 Research and development $ 48,761 $ 25,328 $ 79,688 $ 147,847 General and administrative 182,379 131,817 1,275,213 874,408 Total Stock-based compensation $ 231,140 $ 157,145 $ 1,354,901 $ 1,022,255 The following table summarizes the stock option activity during the six months ended June 30, 2021: Summary of Stock Option Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2020 5,801,349 $ 0.90 8.52 $ 2,773 Granted 1,670,000 $ 1.20 — $ — Exercised (556,540 ) $ 0.48 — $ — Forfeited (417,167 ) $ 1.24 — $ — Outstanding at June 30, 2021 6,497,642 $ 0.99 7.26 $ 759,709 Exercisable at June 30, 2021 5,564,305 $ 1.00 6.96 $ 677,808 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock as of December 31, 2020 and June 30, 2021, respectively. Total unrecognized compensation cost related to unvested stock options was $ 442,856 As of June 30, 2021, 955,068 Each executive officer and non-employee director receiving equity-based awards is subject to a minimum dollar value stock ownership holding requirement with respect to the awards received as well as all prior equity awards under the Plan which requirements are intended to align the ability to sell shares with the performance of the Company’s stock price. The executive officer recipients each have a minimum dollar value stock ownership holding requirement threshold equal to two times (2x) their then base salaries below which dollar threshold they would be precluded from selling any shares of Company stock obtained from the Company under its Plan. Also, the non-employee directors are each subject to a minimum dollar value stock ownership holding requirement threshold equal to six times the annual Board retainer ($ 270,000 The Company entered into a separation agreement with its former chief executive officer which provided for severance payments as contemplated by his employment agreement and (i) accelerated the vesting of certain outstanding option awards; and (ii) extended the time for the exercise of certain vested options for one year from the date of separation. The former executive exercised options to acquire 400,000

Warrants

Warrants	6 Months Ended
	Jun. 30, 2021
Warrants
Warrants	6. Warrants During the three months ended March 31, 2021, 2,472,573 360,000 1.00 2,112,573 0.90 2,261,336 During the three months ended September 30, 2020, the Company issued an additional 5,642,114 760,000 1.00 4,882,114 0.90 5,153,902 On May 14, 2020 warrants to acquire 9,545,334 On May 1, 2020, the Company issued warrants to acquire 9,200,000 1.25 five-year A summary of warrant activity for the year ended December 31, 2020 and the six months ended June 30, 2021 is as follows: Schedule of Warrants Activity Warrants Weighted Average Price Balance - December 31, 2019 26,538,593 $ 1.08 Granted 9,200,000 1.25 Exercised (5,680,114 ) 0.91 Expired (9,545,334 ) 0.75 Balance - December 31, 2020 20,513,145 1.36 Balance - December 31, 2020 20,513,145 1.36 Granted — — Exercised (2,472,573 ) 0.91 Expired — — Balance - June 30, 2021 18,040,572 $ 1.42 The warrants outstanding as of June 30, 2021 are as follows: Schedule of Warrants Outstanding Exercise Price Warrants Expiration $ 3.10 48,387 9/19/2022 $ 2.00 900,000 4/10/2023 $ 3.10 462,106 5/10/2024 $ 3.10 602,414 7/25/2024 $ 3.10 1,064,518 11/8/2024 $ 1.00 3,174,500 7/17/2025 $ 0.90 2,588,647 3/25/2024 $ 1.25 9,200,000 5/1/2025 18,040,572 All outstanding warrants are classified as equity on the Company’s Consolidated Balance Sheets.

Short-Term Notes Payable

Short-Term Notes Payable	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Short-Term Notes Payable	7. Short-Term Notes Payable As of June 30, 2021 and December 31, 2020, the Company had $ — 228,227 Products Liability Insurance On March 10, 2019, the Company entered into a short-term note payable for $ 17,688 5.69 11 February 14, 2020 Directors’ and Officers’ Insurance On July 24, 2020, the Company entered into a short-term note payable for $ 413,784 5.39 11 June 28, 2021 On August 7, 2019 the Company entered into a short-term note payable for $ 254,889 5.74 11 June 22, 2020

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Additional Consideration-NTI Acquisition. In connection with the Company’s acquisition of NTI on May 1, 2020, the Company is obligated to pay the former sole shareholder of NTI contingent consideration based upon the exercise of certain of the Company’s outstanding warrants as follows: (i) twenty percent ( 20 0.90 45 1.00 As a result of warrant exercises during the three months ended March 31, 2021, 2,472,573 warrants were exercised as follows: (i) 360,000 shares at an exercise price of $ 1.00 per share and (ii) 2,112,573 at an exercise price of $ 0.90 per share 542,263 no NIH License Through NTI, the Company is a party to a Patent License and Biological Materials License Agreement (the “License Agreement” or “NIH License”), dated March 23, 2020, with the United States Department of Health and Human Services (the “HHS”), as represented by the National Institute of Allergy and Infectious Diseases (“NIAID”), an Institute within the National Institutes of Health (“NIH”). Under the terms of the License Agreement, we hold a nonexclusive, worldwide license to certain specified patent rights (including patent applications, provisional patent applications and Patent Cooperation Treaty (“PCT”) patent applications) and biological materials relating to the use of pre-fusion coronavirus spike proteins to exploit products (“Licensed Products”) and practice processes (“Licensed Processes”) that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for SARS-CoV-2. Under the terms of the License Agreement, the NIAID is entitled to receive a non-creditable, nonrefundable upfront license issue royalty of $ 30,000 11,739 The License Agreement will expire upon (a) twenty ( 20 The Lantibiotic ECC On March 1, 2021, we entered into an amended and restated worldwide exclusive channel collaboration agreement with Eleszto Genetika, Inc. (“EGI”) (the “Lantibiotic ECC”) in which we will use its advanced transgene and cell engineering platforms for the development and production of lantibiotics, a class of peptide antibiotics that are naturally produced in Gram-positive bacteria and contain the characteristic polycyclic thioether amino acids lanthionine and methyllanthonine (collectively, the “Lantibiotics Program”). The Lantibiotic ECC grants us an exclusive worldwide license to use patents and other intellectual property of EGI in connection with the research, development, use, importing, exporting, manufacture, sale, and offer for sale of drug products involving the direct administration to humans or companion animals of a lantibiotic for the prevention or treatment of infectious disease (“Oragenics Products”). Such license is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of Oragenics Products, and otherwise is non-exclusive. Subject to limited exceptions, we may not sublicense the rights described without Precigen’s written consent. Under the terms of the Lantibiotic ECC, we have agreed to make certain payments, in cash, to our Collaboration Partner upon our achievement of designated milestones. The milestone events and amounts payable are as follows: (i) a one-time payment of twenty-five million United States dollars ($ 25,000,000 6 (ii) a one-time payment of five million United States dollars ($ 5,000,000 6 (iii) a one-time payment of five million United States dollars ($ 5,000,000 6 None of the Lantibiotic ECC milestones had been achieved as of June 30, 2021. Leases The Company’s Alachua facility is being leased from a real estate developer for a term of five years 12,870 13,338 In November of 2016, the Company entered into an amendment for the leased office space for corporate personnel located in Tampa, FL. The amended lease is for approximately 2,207 thirty-six months 4,138 4,392 February 29, 2020 three years 4,524 4,800 Supplemental balance sheet information related to leases is as follows: Schedule of Supplemental Balance Sheet Information Related to Leases June 30, 2021 December 31, 2020 Weighted Average Remaining Lease Term In Years Operating leases 2.96 3.46 Weighted Average Discount Rate Operating leases 5.70 % 5.70 % Maturities of operating lease liabilities are as follows: Schedule of Maturities of Operating Lease Liabilities Year ended December 31: Jun. 30, 2021 2021 $ 105,651 2022 217,379 2023 169,656 2024 146,719 Total $ 639,405 Less: Imputed interest (55,539 ) Present value of lease liabilities $ 583,866 The cost component of operating leases is as follows: Schedule of Cost Component of Operating Leases For the Six Months Ended June 30, 2021 For The Six Months Ended June 30, 2020 Operating lease cost $ 114,002 $ 112,162 Short-term lease cost 782 738 Total lease cost $ 114,784 $ 112,900 Supplemental cash flow information related to operating leases is as follows: Schedule of Supplemental Cash Flow Information Related to Operating Leases For the Six Months Ended June 30, 2021 For The Six Months Ended June 30, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 113,454 $ 112,846

Shareholders_ Equity

Shareholders’ Equity	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Shareholders’ Equity	9. Shareholders’ Equity Common Stock During three months ended June 30, 2021, the Company issued 556,540 During the three months ended March 31, 2021, the Company issued an aggregate of 23,871,338 21,398,765 27.8 2,472,573 2.3 Preferred Stock Series C Preferred Stock Dividend and Redemption During the three months ended March 31, 2021, the Company provided a notice of redemption, to the holder of the Company’s Series C Preferred Stock to redeem all outstanding Series C Preferred Stock (which included the dividend of 26.697 5.6

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of Oragenics, Inc. and our wholly-owned subsidiary Noachis Terra, Inc. All intercompany balances and transactions have been eliminated.
New Accounting Standards	New Accounting Standards There are no additional accounting pronouncements issued or effective during the three and six months ended June 30, 2021, that have had, or are expected to have, a material impact on our consolidated financial statements.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Income Taxes In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company’s adoption of the provisions of ASU No. 2019-12, did not have an impact on its consolidated financial statements and related disclosures.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the consolidated financial statements are stock-based compensation, and valuation of warrants.
Stock-Based Payment Arrangements	Stock-Based Payment Arrangements Generally, all forms of stock-based payments, including stock option grants, and warrants are measured at their fair value on the awards’ grant date using a Black-Scholes pricing model. Stock-based compensation awards issued to non-employees for services rendered are recorded at the fair value of the stock-based payment. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided. Stock-based payment expense is recorded over the requisite service period in which the grantee provides services to us. To the extent the stock option grants, warrants, or restricted stock grants do not vest at the grant date they are subject to forfeiture.
Stock-Based Compensation	Stock-Based Compensation US GAAP requires all stock-based payments to employees, including grants of employee stock options, to be recognized in the consolidated financial statements based on their fair values as of the grant date. Stock-based compensation expense is recorded over the requisite service period in which the grantee provides services to us, to the extent the options do not vest at the grant date and are subject to forfeiture. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met. In connection with adopting ASU 2016-09, the Company made an accounting policy election to account for forfeitures in compensation expense as they occur.
Warrants	Warrants The Company used the Black Scholes Option Pricing Model in calculating the relative fair value of any warrants that have been issued.
Net Loss Per Share	Net Loss Per Share During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive because the Company reported a net loss for all periods presented. Basic and diluted net loss per share amounts are the same for the periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding.
Concentrations	Concentrations Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of June 30, 2021, the uninsured portion of this balance was $ 34,324,769 17,389,575

Acquisition (Tables)

Acquisition (Tables)	6 Months Ended
	Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Common Stock, and Contingent Cash Consideration	Schedule of Common Stock, and Contingent Cash Consideration Fair Value Cash - Initial Cash Payment $ 1,925,000 Equity - Common Stock 4,627,600 Equity - Warrants 3,403,099 Total fair value of consideration $ 9,955,699

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense Recognized	The Company recognized stock-based compensation on all employee and non-employee awards as follows: Schedule of Stock-based Compensation Expense Recognized For the Three Months Ended June 30, 2021 For the Three Months Ended June 30, 2020 For the Six Months Ended June 30, 2021 For the Six Months Ended June 30, 2020 Research and development $ 48,761 $ 25,328 $ 79,688 $ 147,847 General and administrative 182,379 131,817 1,275,213 874,408 Total Stock-based compensation $ 231,140 $ 157,145 $ 1,354,901 $ 1,022,255
Summary of Stock Option Activity	The following table summarizes the stock option activity during the six months ended June 30, 2021: Summary of Stock Option Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2020 5,801,349 $ 0.90 8.52 $ 2,773 Granted 1,670,000 $ 1.20 — $ — Exercised (556,540 ) $ 0.48 — $ — Forfeited (417,167 ) $ 1.24 — $ — Outstanding at June 30, 2021 6,497,642 $ 0.99 7.26 $ 759,709 Exercisable at June 30, 2021 5,564,305 $ 1.00 6.96 $ 677,808 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock as of December 31, 2020 and June 30, 2021, respectively.

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2021
Warrants
Schedule of Warrants Activity	A summary of warrant activity for the year ended December 31, 2020 and the six months ended June 30, 2021 is as follows: Schedule of Warrants Activity Warrants Weighted Average Price Balance - December 31, 2019 26,538,593 $ 1.08 Granted 9,200,000 1.25 Exercised (5,680,114 ) 0.91 Expired (9,545,334 ) 0.75 Balance - December 31, 2020 20,513,145 1.36 Balance - December 31, 2020 20,513,145 1.36 Granted — — Exercised (2,472,573 ) 0.91 Expired — — Balance - June 30, 2021 18,040,572 $ 1.42
Schedule of Warrants Outstanding	The warrants outstanding as of June 30, 2021 are as follows: Schedule of Warrants Outstanding Exercise Price Warrants Expiration $ 3.10 48,387 9/19/2022 $ 2.00 900,000 4/10/2023 $ 3.10 462,106 5/10/2024 $ 3.10 602,414 7/25/2024 $ 3.10 1,064,518 11/8/2024 $ 1.00 3,174,500 7/17/2025 $ 0.90 2,588,647 3/25/2024 $ 1.25 9,200,000 5/1/2025 18,040,572

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases is as follows: Schedule of Supplemental Balance Sheet Information Related to Leases June 30, 2021 December 31, 2020 Weighted Average Remaining Lease Term In Years Operating leases 2.96 3.46 Weighted Average Discount Rate Operating leases 5.70 % 5.70 %
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities are as follows: Schedule of Maturities of Operating Lease Liabilities Year ended December 31: Jun. 30, 2021 2021 $ 105,651 2022 217,379 2023 169,656 2024 146,719 Total $ 639,405 Less: Imputed interest (55,539 ) Present value of lease liabilities $ 583,866
Schedule of Cost Component of Operating Leases	The cost component of operating leases is as follows: Schedule of Cost Component of Operating Leases For the Six Months Ended June 30, 2021 For The Six Months Ended June 30, 2020 Operating lease cost $ 114,002 $ 112,162 Short-term lease cost 782 738 Total lease cost $ 114,784 $ 112,900
Schedule of Supplemental Cash Flow Information Related to Operating Leases	Supplemental cash flow information related to operating leases is as follows: Schedule of Supplemental Cash Flow Information Related to Operating Leases For the Six Months Ended June 30, 2021 For The Six Months Ended June 30, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 113,454 $ 112,846

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Accounting Policies [Abstract]
Net loss	$ 3,815,347	$ 5,219,945	$ 12,337,296	$ 5,187,760	$ 9,035,292	$ 17,525,056
Cash used in operations					6,405,775	$ 8,655,695
Accumulated deficit	$ 164,597,806				$ 164,597,806		$ 154,444,983

Significant Accounting Polici_3

Significant Accounting Policies (Details Narrative) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Uninsured portion of balance	$ 34,324,769	$ 17,389,575

Schedule of Common Stock, and C

Schedule of Common Stock, and Contingent Cash Consideration (Details)	6 Months Ended
	Jun. 30, 2021USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash - Initial Cash Payment	$ 1,925,000
Total fair value of consideration	9,955,699
Common Stock [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity	4,627,600
Warrant [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Equity	$ 3,403,099

Acquisition (Details Narrative)

Acquisition (Details Narrative) - USD ($)	May 01, 2020	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	May 14, 2020
Business Acquisition [Line Items]
Payments to acquire business		$ 1,925,000
Fair value of purchase consideration		$ 9,955,699
Warrant [Member]
Business Acquisition [Line Items]
Warrants to purchase shares			2,472,573		9,545,334
Warrant One [Member]
Business Acquisition [Line Items]
Warrants to purchase shares		360,000		760,000
Warrants exercise price per share		$ 1		$ 1
Noachis Terra Inc [Member] | Warrant [Member]
Business Acquisition [Line Items]
Warrants to purchase shares	9,200,000
Warrants exercise price per share	$ 1.25
Warrants term	5 years
Stock Purchase Agreement [Member]
Business Acquisition [Line Items]
Fair value of purchase consideration	$ 9,955,699
Stock Purchase Agreement [Member] | Twenty Percent Cash Proceeds Exercise Warrants Two [Member] | Mr. Joseph Hernandez [Member]
Business Acquisition [Line Items]
Warrants exercise price per share	$ 0.75
Stock Purchase Agreement [Member] | Twenty Percent Cash Proceeds Exercise Warrants [Member] | Mr. Joseph Hernandez [Member]
Business Acquisition [Line Items]
Warrants exercise price per share	0.90
Stock Purchase Agreement [Member] | Warrant One [Member] | Mr. Joseph Hernandez [Member]
Business Acquisition [Line Items]
Warrants exercise price per share	$ 1
Percentage of warrant exercise	45.00%
Stock Purchase Agreement [Member] | Noachis Terra Inc [Member]
Business Acquisition [Line Items]
Payments to acquire business	$ 1,925,000
Pretransaction liabilities	$ 500,000
Number of restricted shares issued	9,200,000
Stock Purchase Agreement [Member] | Noachis Terra Inc [Member] | Warrant [Member]
Business Acquisition [Line Items]
Warrants to purchase shares	9,200,000
Warrants exercise price per share	$ 1.25
Warrants term	5 years
Contingent consideration description	(i) twenty percent (20%) of the cash proceeds received by the Company upon exercise of the Company’s warrants carrying an exercise price of $0.75 and $0.90 and (ii) forty-five percent (45%) of the cash proceeds received by the Company upon exercise of the Company’s warrants carrying an exercise price of $1.00, in each case, for so long as the warrants remain outstanding.
Percentage of warrant exercise	20.00%
Stock Purchase Agreement [Member] | Noachis Terra Inc [Member] | Warrant One [Member]
Business Acquisition [Line Items]
Percentage of warrant exercise	45.00%
Stock Purchase Agreement [Member] | Noachis Terra Inc [Member] | Warrant One [Member] | Mr. Joseph Hernandez [Member]
Business Acquisition [Line Items]
Warrants exercise price per share	$ 1
Stock Purchase Agreement [Member] | Noachis Terra Inc [Member]
Business Acquisition [Line Items]
Business acquisition percentage	100.00%

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expense Recognized (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-based compensation	$ 231,140	$ 157,145	$ 1,354,901	$ 1,022,255
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-based compensation	48,761	25,328	79,688	147,847
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-based compensation	$ 182,379	$ 131,817	$ 1,275,213	$ 874,408

Summary of Stock Option Activit

Summary of Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Share-based Payment Arrangement [Abstract]
Number of Options, Outstanding, Beginning Balance | shares	5,801,349
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.90
Weighted Average Contractual Term, Outstanding Beginning	8 years 6 months 7 days
Aggregate Intrinsic Value Outstanding, Beginning | $	$ 2,773	[1]
Number of Options Outstanding, Granted | shares	1,670,000
Weighted Average Exercise Price, Granted | $ / shares	$ 1.20
Number of Options Outstanding, Exercised | shares	(556,540)
Weighted Average Exercise Price, Exercised | $ / shares	$ 0.48
Number of Options Outstanding, Forfeited | shares	(417,167)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 1.24
Number of Options Outstanding, Ending Balance | shares	6,497,642
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 0.99
Weighted Average Contractual Term, Outstanding Ending	7 years 3 months 3 days
Aggregate Intrinsic Value Outstanding, Ending | $	$ 759,709	[1]
Number of Options Outstanding, Exercisable Ending Balance | shares	5,564,305
Weighted Average Exercise Price, Exercisable Ending Balance | $ / shares	$ 1
Weighted Average Contractual Term, Exercisable Ending	6 years 11 months 15 days
Aggregate Intrinsic Value Exercisable, Ending | $	$ 677,808	[1]
[1]	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock as of December 31, 2020 and June 30, 2021, respectively.

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative)	6 Months Ended
	Jun. 30, 2021USD ($)shares
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Unrecognized compensation cost related to unvested stock options | $	$ 442,856
Number of shares of common stock are available for future awards	955,068
Exercised options to acquire shares of common stock	556,540
Non Employee Directors [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Annual retainer amount for the threshold of stock precluded from selling | $	$ 270,000
Former Chief Executive Officer [Member] | Separation Agreement [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Exercised options to acquire shares of common stock	400,000

Schedule of Warrants Activity (

Schedule of Warrants Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Warrants
Warrants, Beginning balance	20,513,145	26,538,593
Weighted Average Price, Beginning balance	$ 1.36	$ 1.08
Warrants, Granted		9,200,000
Weighted Average Price, Granted		$ 1.25
Warrants, Exercised	(2,472,573)	(5,680,114)
Weighted Average Price, Exercised	$ 0.91	$ 0.91
Warrants, Expired		(9,545,334)
Weighted Average Price, Expired		$ 0.75
Warrants, Ending balance	18,040,572	20,513,145
Weighted Average Price, Ending balance	$ 1.42	$ 1.36
Warrants, Expired		9,545,334

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details)	Jun. 30, 2021$ / sharesshares
Class of Warrant or Right [Line Items]
Warrants Outstanding	18,040,572
Range One [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 3.10
Warrants Outstanding	48,387
Expiration Date	Sep. 19, 2022
Range Two [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 2
Warrants Outstanding	900,000
Expiration Date	Apr. 10, 2023
Range Three [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 3.10
Warrants Outstanding	462,106
Expiration Date	May 10, 2024
Range Four [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 3.10
Warrants Outstanding	602,414
Expiration Date	Jul. 25, 2024
Range Five [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 3.10
Warrants Outstanding	1,064,518
Expiration Date	Nov. 8, 2024
Range Six [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 1
Warrants Outstanding	3,174,500
Expiration Date	Jul. 17, 2025
Range Seven [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 0.90
Warrants Outstanding	2,588,647
Expiration Date	Mar. 25, 2024
Range Eight [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 1.25
Warrants Outstanding	9,200,000
Expiration Date	May 1, 2025

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Sep. 30, 2020	Jun. 30, 2021	Mar. 31, 2021	May 14, 2020	May 01, 2020
Warrant [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of common stock issued in offering	5,642,114	2,472,573
Warrants to purchase shares of common stock			2,472,573	9,545,334
Proceeds from warrant exercises	$ 5,153,902	$ 2,261,336
Warrant [Member] | Noachis Terra Inc [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Warrants to purchase shares of common stock					9,200,000
Warrants exercise price per share					$ 1.25
Term of warrants					5 years
Warrant One [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Warrants to purchase shares of common stock	760,000	360,000
Warrants exercise price per share	$ 1	$ 1
Warrant Two [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Warrants to purchase shares of common stock	4,882,114	2,112,573
Warrants exercise price per share	$ 0.90	$ 0.90

Short-Term Notes Payable (Detai

Short-Term Notes Payable (Details Narrative) - USD ($)	Jul. 24, 2020	Aug. 07, 2019	Mar. 10, 2019	Jun. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Short-term notes payable					$ 228,227
Product Liability Insurance [Member] | Short-term Note Payable [Member]
Short-term Debt [Line Items]
Short-term notes payable			$ 17,688
Debt interest rate			5.69%
Amortization period of debt			11 months
Debt maturity date			Feb. 14, 2020
Directors' and Officers' Insurance [Member] | Short-term Note Payable [Member]
Short-term Debt [Line Items]
Short-term notes payable	$ 413,784	$ 254,889
Debt interest rate	5.39%	5.74%
Amortization period of debt	11 months	11 months
Debt maturity date	Jun. 28, 2021	Jun. 22, 2020

Schedule of Supplemental Balanc

Schedule of Supplemental Balance Sheet Information Related to Leases (Details)	Jun. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Weighted Average Remaining Lease Term In Years, Operating leases	2 years 11 months 15 days	3 years 5 months 15 days
Weighted Average Discount Rate, Operating leases	5.70%	5.70%

Schedule of Maturities of Opera

Schedule of Maturities of Operating Lease Liabilities (Details)	Jun. 30, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021	$ 105,651
2022	217,379
2023	169,656
2024	146,719
Total	639,405
Less: Imputed interest	(55,539)
Present value of lease liabilities	$ 583,866

Schedule of Cost Component of O

Schedule of Cost Component of Operating Leases (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 114,002	$ 112,162
Short-term lease cost	782	738
Total lease cost	$ 114,784	$ 112,900

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 113,454	$ 112,846

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)	Mar. 01, 2021USD ($)	May 01, 2020$ / sharesshares	Nov. 30, 2019USD ($)	Nov. 30, 2016USD ($)ft²	Mar. 31, 2021USD ($)$ / sharesshares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Sep. 30, 2020$ / sharesshares	May 14, 2020shares	Dec. 31, 2019
Product Liability Contingency [Line Items]
Monthly lease payments						$ 113,454	$ 112,846
Alachua Facility [Member]
Product Liability Contingency [Line Items]
Period of lease										5 years
Amended Lease Agreement [Member] | Minimum [Member]
Product Liability Contingency [Line Items]
Monthly lease payments						12,870
Payments of rent						$ 13,338
Tampa Facility [Member]
Product Liability Contingency [Line Items]
Period of lease			3 years	36 months
Area of office space leased | ft²				2,207
Lease expiry date				Feb. 29, 2020
Tampa Facility [Member] | Minimum [Member]
Product Liability Contingency [Line Items]
Monthly lease payments			$ 4,524	$ 4,138
Tampa Facility [Member] | Maximum [Member]
Product Liability Contingency [Line Items]
Monthly lease payments			$ 4,800	$ 4,392
Range One [Member]
Product Liability Contingency [Line Items]
Warrants exercise price per share | $ / shares						$ 3.10
Range Two [Member]
Product Liability Contingency [Line Items]
Warrants exercise price per share | $ / shares						2
Warrant [Member]
Product Liability Contingency [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares					2,472,573				9,545,334
Payment for Contingent Consideration Liability, Operating Activities					$ 542,263
Warrant [Member] | Range One [Member]
Product Liability Contingency [Line Items]
Warrants exercise price per share | $ / shares					$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares					360,000
Warrant [Member] | Range Two [Member]
Product Liability Contingency [Line Items]
Warrants exercise price per share | $ / shares					$ 0.90
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares					2,112,573
Warrant One [Member]
Product Liability Contingency [Line Items]
Warrants exercise price per share | $ / shares						$ 1		$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares						360,000		760,000
Noachis Terra Inc [Member] | Warrant [Member]
Product Liability Contingency [Line Items]
Warrants exercise price per share | $ / shares		$ 1.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		9,200,000
Stock Purchase Agreement [Member] | Twenty Percent Cash Proceeds Exercise Warrants [Member] | Mr. Joseph Hernandez [Member]
Product Liability Contingency [Line Items]
Warrants exercise price per share | $ / shares		$ 0.90
Stock Purchase Agreement [Member] | Warrant One [Member] | Mr. Joseph Hernandez [Member]
Product Liability Contingency [Line Items]
Percentage of warrant exercise		45.00%
Warrants exercise price per share | $ / shares		$ 1
Stock Purchase Agreement [Member] | Noachis Terra Inc [Member] | Warrant [Member]
Product Liability Contingency [Line Items]
Contingent consideration description		(i) twenty percent (20%) of the cash proceeds received by the Company upon exercise of the Company’s warrants carrying an exercise price of $0.90 and (ii) forty-five percent (45%) of the cash proceeds received by the Company upon exercise of the Company’s warrants carrying an exercise price of $1.00, in each case, for so long as the warrants remain outstanding.
Percentage of warrant exercise		20.00%
Warrants exercise price per share | $ / shares		$ 1.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		9,200,000
Stock Purchase Agreement [Member] | Noachis Terra Inc [Member] | Warrant One [Member]
Product Liability Contingency [Line Items]
Percentage of warrant exercise		45.00%
Stock Purchase Agreement [Member] | Noachis Terra Inc [Member] | Warrant One [Member] | Mr. Joseph Hernandez [Member]
Product Liability Contingency [Line Items]
Warrants exercise price per share | $ / shares		$ 1
License Agreement [Member]
Product Liability Contingency [Line Items]
Royalty expenses						$ 30,000
Reimbursement expenses						$ 11,739
Agreement expiration term						20 years
Lantibiotic Exclusive Channel Collaboration [Member] | Regulatory Approval Milestone Event [Member]
Product Liability Contingency [Line Items]
Milestone payment under licensing agreement	$ 25,000,000
Milestone measurement period	6 months
Lantibiotic Exclusive Channel Collaboration [Member] | New Indication Milestone Event [Member]
Product Liability Contingency [Line Items]
Milestone payment under licensing agreement	$ 5,000,000
Milestone measurement period	6 months
Lantibiotic Exclusive Channel Collaboration [Member] | New Product Milestone Event [Member]
Product Liability Contingency [Line Items]
Milestone payment under licensing agreement	$ 5,000,000
Milestone measurement period	6 months

Shareholders_ Equity (Details N

Shareholders’ Equity (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Mar. 15, 2021	Jan. 28, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued upon exercise of stock options			556,540
Gross proceeds from common stock			$ 26,676,392
Warrants outstanding	18,040,572		18,040,572
Series C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Redemption of preferred shares						26.697
Redemption of preferred stock					$ 5,600,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued upon exercise of stock options	556,540
Number of shares issued during the period		23,871,338
Gross proceeds from common stock	$ 27,800,000
Warrants outstanding	2,472,573		2,472,573
Gross proceeds from warrants			$ 2,300,000
Common Stock [Member] | ATM Program [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during the period		21,398,765